INTRODUCTION
With the participation of vitamin K, vitamin K-dependent coagulation factors II, VII, IX and X synthesize in the liver. In the molecular structure of these coagulation factors, there are different numbers of γ carboxyglutamic acid (γ-Gla) residues, which locate in the N-terminal of their own genes. [1] In physiological conditions, these glutamate residues have γ carboxylation reaction catalyzed by the carboxyl enzyme, while vitamin K is essential for the enzymatic reaction. When vitamin K lacks, the γ carboxylation level decreased in the above coagulation factors, which synthesize in the liver without any function.
Although these abnormal proteins have antigen function, they are not combined with phospholipid and Ca 2+ in the normal way, and can't play a normal role in blood clotting or anticoagulant activity. This is called vitamin K-dependent coagulation factor deficiency (VKCFD). In adults, VKCFD has been reported to increase in the recent years. We treated a VKCFD patient with subarachnoid hemorrhage, with favorable outcomes.
Case report
A 19-year-old male student was admitted to a local hospital because of hematuria, low back pain, blood vesicles in the oral cavity, and epistaxis half a month ago. The results of blood examination were normal, and the patient was diagnosed with urinary calculi and nephritis. He was given anti-infective therapy and hemostasis, but the treatment was not sensitive. He was transferred to the 100th Hospital of People's Liberation Army in Suzhou on December 18, 2009. He complained of headache and vomiting for 3 days. Blood routine examination showed WBC 13.5×10 9 /L, Hb 142g/L, and Plt 333×10 9 /L. His BP was 130/85 mmHg, and heart rate 86 beats/min. Head CT showed subarachnoid hemorrhage ( Figure 1) . Ultrasonography of the kidney on both sides showed mild effusion in the left kidney and mild expansion in the upper part of the left ureter. Chest radiograph, electrocardiogram, abdominal ultrasound were normal. The results of urinary red blood cell morphology revealed that red blood cells were of isotype. Glomerular disease was excluded. Routine coagulation tests revealed that activated partial thromboplastin time (APTT)>120 seconds, prothrombin time (PT)>120 seconds, thrombin time (TT) and fi brinogen (Fg) were normal. Hemophilia was not excluded. During the course, the patient had no chills, fever, cough, or sputum, but he felt nausea and vomiting. The quality of diet and sleep was poor, but the stool was normal. He was healthy before, and had no history of hepatitis nor long-term of diarrhea or use of antibiotics. He denied the history of gastrointestinal surgery, urinary calculi, bleeding and family history of bleeding.
He was monitored with an ECG monitor, and injected with 1000 ml blood plasma per day for 3 days and 80 mg vitamin K1 daily. After treatment for 6 hours, urine color was bright, and one day after treatment no hematuria appeared. At 3 days after treatment, APTT was 41.6 seconds, and PT 17.4 seconds; TT, Fg, and vWF were normal. The results of plasma protamine paracogulation (3P) test were negative. FC: II 81%, FC: VII 34%, FC: IX 37%, and FC: X 63%. At 6 days after stopping the use of plasma, the above clotting factors were tested again and showed a decreasing tendency. After administration of a larger dose of vitamin K1 (a maximum dose of 240 mg/d), the clotting factors returned to normal at 4 weeks. At 2 weeks after admission, head MRI showed that subarachnoid hemorrhage was absorbed, and malformation of cerebral vascular was not observed (Figure 2 ). The focus of hemorrhage subsided, neurological examination was normal, and the patient was discharged at 4 weeks after admission. After discharge, the patient was injected with 60 mg vitamin K1 twice per week. At 4 weeks after discharge, routine coagulation test showed APTT 74 seconds, PT 55.3 seconds; normal TT, Fg, and vWF; negative 3P test; FC: II 17%, FC: VII 3%, FC: IX 4%, and FC: X 17%. The patient took oral vitamin K4 (240 mg/d), and did not develop any hemorrhage (Table 1) . After injection of a large dose of vitamin K1, he experienced side-effects such as flushing, palpitation, which disappeared after slowing down the injection speed. The patient had no side-effects after administration of vitamin K4. 
DISCUSSION
VKCFD is relatively rare, and the severity of hemorrhage differs [2] because of congenital insufficient intake of vitamin K, intestinal malabsorption, reduced intestinal synthesis, antagonist poisoning, and severe liver disease. [3, 4] At present no diagnostic criteria are available for this disease. Our patient was diagnosed according to the following criteria: (1) hemorrhage; (2) prolonged or increased APTT, PT, and INR; (3) responsible to high dose of vitamin K1; (4) exclusion of hereditary coagulation factor deficiency disease; (5) decreased activity of coagulation factor II, VII, IX or X. 
